Atopy Patch Test induced TSLP expression in atopic dermatitis skin.
- Conditions
- atopic dermatitis (AD)eczema10014982
- Registration Number
- NL-OMON36868
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 5
age 18-70 years
AD
positive APT during previous study (NL32336.041.10 or 10-161 METC UMCU) and local TSLP mRNA (qPCR) and protein expression (immunohistochemistry) detectable in skinbiopsy material from testsite.
- Active AD on the back
- LSS >30
- Not sensitized to aeroallergens, such as house dust mite (demonstrated by a positive Immuno CAP test for these allergens).
- Treatment with systemic corticosteroid or other immunosuppressive medication (such as cyclosporin) within the 4 weeks prior to having the biopsies performed. In addition, weekly use of equal or more than 50 grams of topical corticosteroids class IV or weekly use of equal or more than 100 grams of topical corticosteroids class III.
- Treatment of the biopsy and APT regions not restricted to indifferent topical treatment in the 2 weeks prior
- Exposure of biopsy location to UV sunlicht (e.g. UV-therapy, sunny holiday) in the 2 weeks prior to taking biopsies.
- Use of coumarin derivatives
- Use of antihistamines in the week or days before and during the APT (see patientinformation 'Bijlage 4: Medicatielijst').
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>In vivo: TSLP mRNA expression level (qPCR or quantitative Polymerase Chain<br /><br>Reaction) in cryosections from skin biopsy material (quantitative). </p><br>
- Secondary Outcome Measures
Name Time Method <p>Immunohistochemical staining for TSLP protein and other related products in<br /><br>cryosections from skin biopsy material (qualitative; determining presence and<br /><br>localization). </p><br>